The alpha interferons have recently undergone extensive phase I and II investigation in numerous tumour sites. The antineoplastic activity of various alpha interferon preparations in renal cell carcinoma has been documented by several investigators (Quesada et al., 1983 (Quesada et al., , 1985 Neidhart et al., 1984; Kirkwood et al., 1985) . In all of these studies the interferon was administered as a daily or three times weekly intramuscular injection.
Recently, Connors and Silver (1984) reported the results of a phase I trial in which human lymphoblastoid interferon was given in a novel weekly i.v. bolus schedule. Doses were escalated according to patient tolerance. No myelosuppression or hepatic dysfunction was detected. The primary toxicities were chills, fever, myalgia and fatigue.
Following the completion of this phase I study, the National Cancer Institute of Canada Clinical Trials Group initiated a phase II study of interferon given in this schedule in patients with advanced renal cell carcinoma. The results of this study are the subject of this report.
Patients with histologically documented measurable advanced renal cell carcinoma were entered into the study. Patients were eligible if they had an ECOG (Eastern Cooperative Oncology Group) performance status of 0, 1 or 2; absolute granulocyte count > 1,500mm-, platelet count > 125,000 mm 3, serum creatinine < 250 4umol 1 1, liver enzymes no greater than twice the upper limit of normal, no major cardiac disease and no more than one previous systemic therapy. Patients All 39 remaining patients were evaluable for toxicity and 37 were evaluable for response. Two were considered inevaluable for response: 1 went off study because of toxicity after only 1 dose of interferon and the other had a presumed pulmonary embolus and went off study after 2 doses of interferon.
Patient characteristics are described in Table I Other investigators utilizing different schedules of interferon alpha have reported response rates in renal cell carcinoma ranging from 7-26% (Quesada et al., 1983 (Quesada et al., , 1985 Neidhart et al., 1984; Kirkwood et al., 1985) . Weekly administration produced a comparable response rate and was practical and acceptable to the majority of patients. The primary toxicities were fever, chills, malaise and a fall in performance status. Of note, and in keeping with the phase I observations of Connors and Silver (1984) , neither myelosuppression nor hepatotoxicity were seen. The rather low response rates observed in this and other trials in which alpha interferon has been used as a single agent in this disease are disappointing and indicate there is little role for the use of this drug alone in the management of advanced renal cell carcinoma. Future studies with interferon will undoubtedly focus upon its use in combination with other cytotoxic drugs and we feel the attributes of the weekly administration schedule in producing an altered spectrum of toxicity should be considered when planning such trials.
